A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy

Roberto Negro, Laszlo Hegedüs, Roberto Attanasio, Enrico Papini, Kristian H. Winther

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Objective: Selenium (Se) supplementation has been suggested in the treatment of Graves' disease (GD). We sought to investigate Se prescription patterns for GD across European countries. Methods: Members of the European Thyroid Association were invited to participate in an online survey investigating the use of Se in GD either without or with orbitopathy (GO). Of 872 invited members, 244 (28%) completed the survey. After exclusion of basic scientists and non-European members, 197 responses were retrieved out of clinical trials (nearly half of clinician members), of whom 61 do not use Se. Thus, 136 respondents remained for further analyses. Results: Among the 136 analyzed respondents, most (64.7%) were not aware of the Se status in their populations, did not assess Se levels (78.7%), nor considered iodine status (74.3%). In GD without GO, 38.2% recommend Se supplementation ("sometimes" [27.2%], "frequently" [5.9%] or "always" [5.1%]). When GO occurs, 94.1% recommend Se supplementation ("sometimes" [39%], "frequently" [30.1%] or "always" [25%]). Of these, 60.1% recommend Se as an alternative to watchful waiting in patients with mild ocular involvement and 44.9% as an adjuvant to the established treatment modalities in patients with moderate to severe ocular involvement. Conclusions: In Graves' hyperthyroidism without GO, 38.2% of ETA (European Thyroid Association) members recommend Se supplementation. Conversely, Se is recommended by the majority of respondents in GO, both in patients with mild and moderate to severe ocular involvement. This clinical practice is partially in disagreement with current European treatment guidelines that recommend Se as a 6-month treatment in mild GO only.

SprogEngelsk
TidsskriftEuropean Thyroid Journal
Vol/bind8
Udgave nummer1
Sider7–15
ISSN2235-0640
DOI
StatusUdgivet - jan. 2019

Fingeraftryk

Selenium
Surveys and Questionnaires
Watchful Waiting
Iodine
Prescriptions
Clinical Trials
Guidelines

Emneord

    Citer dette

    Negro, Roberto ; Hegedüs, Laszlo ; Attanasio, Roberto ; Papini, Enrico ; Winther, Kristian H. / A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy. I: European Thyroid Journal. 2019 ; Bind 8, Nr. 1. s. 7–15.
    @article{409a0458ed9a4a788e550fa3489fad20,
    title = "A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy",
    abstract = "Objective: Selenium (Se) supplementation has been suggested in the treatment of Graves' disease (GD). We sought to investigate Se prescription patterns for GD across European countries. Methods: Members of the European Thyroid Association were invited to participate in an online survey investigating the use of Se in GD either without or with orbitopathy (GO). Of 872 invited members, 244 (28{\%}) completed the survey. After exclusion of basic scientists and non-European members, 197 responses were retrieved out of clinical trials (nearly half of clinician members), of whom 61 do not use Se. Thus, 136 respondents remained for further analyses. Results: Among the 136 analyzed respondents, most (64.7{\%}) were not aware of the Se status in their populations, did not assess Se levels (78.7{\%}), nor considered iodine status (74.3{\%}). In GD without GO, 38.2{\%} recommend Se supplementation ({"}sometimes{"} [27.2{\%}], {"}frequently{"} [5.9{\%}] or {"}always{"} [5.1{\%}]). When GO occurs, 94.1{\%} recommend Se supplementation ({"}sometimes{"} [39{\%}], {"}frequently{"} [30.1{\%}] or {"}always{"} [25{\%}]). Of these, 60.1{\%} recommend Se as an alternative to watchful waiting in patients with mild ocular involvement and 44.9{\%} as an adjuvant to the established treatment modalities in patients with moderate to severe ocular involvement. Conclusions: In Graves' hyperthyroidism without GO, 38.2{\%} of ETA (European Thyroid Association) members recommend Se supplementation. Conversely, Se is recommended by the majority of respondents in GO, both in patients with mild and moderate to severe ocular involvement. This clinical practice is partially in disagreement with current European treatment guidelines that recommend Se as a 6-month treatment in mild GO only.",
    keywords = "European Thyroid Association, Graves' disease, Graves' disease treatment, Graves' orbitopathy, Questionnaire, Selenium supplementation",
    author = "Roberto Negro and Laszlo Heged{\"u}s and Roberto Attanasio and Enrico Papini and Winther, {Kristian H.}",
    year = "2019",
    month = "1",
    doi = "10.1159/000494837",
    language = "English",
    volume = "8",
    pages = "7–15",
    journal = "European Thyroid Journal",
    issn = "2235-0640",
    publisher = "S. Karger AG",
    number = "1",

    }

    A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy. / Negro, Roberto; Hegedüs, Laszlo; Attanasio, Roberto; Papini, Enrico; Winther, Kristian H.

    I: European Thyroid Journal, Bind 8, Nr. 1, 01.2019, s. 7–15.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    TY - JOUR

    T1 - A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy

    AU - Negro, Roberto

    AU - Hegedüs, Laszlo

    AU - Attanasio, Roberto

    AU - Papini, Enrico

    AU - Winther, Kristian H.

    PY - 2019/1

    Y1 - 2019/1

    N2 - Objective: Selenium (Se) supplementation has been suggested in the treatment of Graves' disease (GD). We sought to investigate Se prescription patterns for GD across European countries. Methods: Members of the European Thyroid Association were invited to participate in an online survey investigating the use of Se in GD either without or with orbitopathy (GO). Of 872 invited members, 244 (28%) completed the survey. After exclusion of basic scientists and non-European members, 197 responses were retrieved out of clinical trials (nearly half of clinician members), of whom 61 do not use Se. Thus, 136 respondents remained for further analyses. Results: Among the 136 analyzed respondents, most (64.7%) were not aware of the Se status in their populations, did not assess Se levels (78.7%), nor considered iodine status (74.3%). In GD without GO, 38.2% recommend Se supplementation ("sometimes" [27.2%], "frequently" [5.9%] or "always" [5.1%]). When GO occurs, 94.1% recommend Se supplementation ("sometimes" [39%], "frequently" [30.1%] or "always" [25%]). Of these, 60.1% recommend Se as an alternative to watchful waiting in patients with mild ocular involvement and 44.9% as an adjuvant to the established treatment modalities in patients with moderate to severe ocular involvement. Conclusions: In Graves' hyperthyroidism without GO, 38.2% of ETA (European Thyroid Association) members recommend Se supplementation. Conversely, Se is recommended by the majority of respondents in GO, both in patients with mild and moderate to severe ocular involvement. This clinical practice is partially in disagreement with current European treatment guidelines that recommend Se as a 6-month treatment in mild GO only.

    AB - Objective: Selenium (Se) supplementation has been suggested in the treatment of Graves' disease (GD). We sought to investigate Se prescription patterns for GD across European countries. Methods: Members of the European Thyroid Association were invited to participate in an online survey investigating the use of Se in GD either without or with orbitopathy (GO). Of 872 invited members, 244 (28%) completed the survey. After exclusion of basic scientists and non-European members, 197 responses were retrieved out of clinical trials (nearly half of clinician members), of whom 61 do not use Se. Thus, 136 respondents remained for further analyses. Results: Among the 136 analyzed respondents, most (64.7%) were not aware of the Se status in their populations, did not assess Se levels (78.7%), nor considered iodine status (74.3%). In GD without GO, 38.2% recommend Se supplementation ("sometimes" [27.2%], "frequently" [5.9%] or "always" [5.1%]). When GO occurs, 94.1% recommend Se supplementation ("sometimes" [39%], "frequently" [30.1%] or "always" [25%]). Of these, 60.1% recommend Se as an alternative to watchful waiting in patients with mild ocular involvement and 44.9% as an adjuvant to the established treatment modalities in patients with moderate to severe ocular involvement. Conclusions: In Graves' hyperthyroidism without GO, 38.2% of ETA (European Thyroid Association) members recommend Se supplementation. Conversely, Se is recommended by the majority of respondents in GO, both in patients with mild and moderate to severe ocular involvement. This clinical practice is partially in disagreement with current European treatment guidelines that recommend Se as a 6-month treatment in mild GO only.

    KW - European Thyroid Association

    KW - Graves' disease

    KW - Graves' disease treatment

    KW - Graves' orbitopathy

    KW - Questionnaire

    KW - Selenium supplementation

    U2 - 10.1159/000494837

    DO - 10.1159/000494837

    M3 - Journal article

    VL - 8

    SP - 7

    EP - 15

    JO - European Thyroid Journal

    T2 - European Thyroid Journal

    JF - European Thyroid Journal

    SN - 2235-0640

    IS - 1

    ER -